Skip to main content

Table 2 Response to immunotherapy

From: Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?

Response

Total

irAE group

Non-irAE group

p-value

PD

61

14

47

-

SD

9

6

3

-

PR

2

2

0

-

CR

2

2

0

-

ORR

5.4% (95%CI: 0.1% to 10.7%)

16.7% (95%CI: 4.7% to 37.4%)

-

-

DCR

17.6% (95%CI: 8.7% to 26.4%)

41.7% (95%CI: 20.4% to 62.9%)

6.0% (95%CI: 0.0% to 12.8%)

0.001

  1. Abbreviations: SD Stable disease, PR Partial response, PD Progressive disease, CR Complete response, ORR Objective response rate, DCR Disease control rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us